Effects of resveratrol on the inflammatory response and renal injury in hyperuricemic rats

Benxi Xiao; Wenjun Ma; Ying Zheng; Zhen Li; Dan Li; Yanjun Zhang; Yuanhong Li; Duan Wang

doi:10.4162/nrp.2021.15.1.26

Journal List > Nutr Res Pract > v.15(1) > 1146312

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Xiao, Ma, Zheng, Li, Li, Zhang, Li, and Wang: Effects of resveratrol on the inflammatory response and renal injury in hyperuricemic rats

Original Research

Nutrition Research and Practice 2021; 15(1): 26-37.

Published online: 12 August 2020

DOI: https://doi.org/10.4162/nrp.2021.15.1.26

Effects of resveratrol on the inflammatory response and renal injury in hyperuricemic rats

Benxi Xiao¹

, Wenjun Ma¹

, Ying Zheng¹

, Zhen Li¹

, Dan Li²

, Yanjun Zhang¹

, Yuanhong Li¹

, Duan Wang¹

¹Department of Nutrition, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China.

²Department of Nutrition, School of Public Health in Sun Yat-sen University, Guangzhou 510080, China.

Corresponding Author: Duan Wang. Department of Nutrition, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, No. 106 Zhongshan Er Road, Yuexiu District, Guangzhou 510080, China. Tel. +86-020-8382-7812-10077, Fax. +86-020-8382-8480, duanwang2009@163.com.

Received 20 March 2020 Revised 4 May 2020 Accepted 16 July 2020

The Korean Nutrition Society and the Korean Society of Community Nutrition

(open-access, https://creativecommons.org/licenses/by-nc/4.0/):

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

BACKGROUND/OBJECTIVES

Hyperuricemic nephropathy is a common cause of acute kidney injury. Resveratrol can ameliorate kidney injury, but the explicit mechanism remains unclear. We investigated the effects of resveratrol on the inflammatory response and renal injury in hyperuricemic rats.

MATERIALS/METHODS

A rat model of hyperuricemic nephropathy was established by the oral administration of a mixture of adenine and potassium oxinate. Biochemical analysis and hematoxylin and eosin staining were performed to assess the rat kidney function. Enzyme-linked immunosorbent assays were performed to evaluate the immune and oxidative responses.

RESULTS

The expression levels of urine albumin and β2-microglobulin were significantly decreased after resveratrol treatment. In addition, the levels of serum creatinine and uric acid were significantly decreased in the resveratrol groups, compared with the control group. The levels of proinflammatory factors, such as interleukin-1β and tumor necrosis factor-α, in kidney tissue and serum were also increased in the hyperuricemic rats, and resveratrol treatment inhibited their expression. Moreover, the total antioxidant capacity in kidney tissue as well as the superoxide dismutase and xanthine oxidase levels in serum were all decreased by resveratrol treatment.

CONCLUSIONS

Resveratrol may protect against hyperuricemic nephropathy through regulating the inflammatory response.

Keywords: Hyperuricemia, resveratrol, kidney diseases, inflammation, anti-oxidative effect

INTRODUCTION

With the major changes in people's lifestyle and dietary structure in recent years, the prevalence of hyperuricemia has significantly increased [1]. In addition, it has been found that hyperuricemia is an independent risk factor affecting renal function [2], which seriously threatens human health. Renal injury caused by hyperuricemia is mainly triggered by the accumulation of large amounts of uric acid crystals in the collecting ducts, pelvis, and ureters of the kidney during a short period of time. Urate crystals are deposited in renal tissues and block renal tubules, causing acute and chronic uric acid nephropathy and uric acid kidney stones. In patients with long-term hyperuricemia, the renal structure is impaired, which can lead to renal fibrosis formation, glomerulosclerosis, arteriosclerosis, and arterial wall thickening [3]. Currently, allopurinol is the main drug used for the treatment of hyperuricemia, but serious side effects such as allergic reactions and damage to the blood system, liver, and kidney limit its clinical application [4]. Resveratrol does not have such side effects. In this study, the effects of resveratrol on the inflammatory response and renal injury in hyperuricemic rats were investigated.

Resveratrol is a polyphenolic compound, chemically known as 3,5,4′-trihydroxystyrene, which was first extracted from white hellebore in 1940. Animal studies on the protection of renal function by resveratrol have focused on diabetes [5], gestational diabetes, a high-fat diet [6], a high-sugar diet, and other rat models [7]. Additionally, resveratrol has been reported to exhibit nephroprotective effects in potassium oxinate-induced hyperuricemic mice [8]. Moreover, the expression of organic ion transporter protein is increased in this model. Despite these findings, the mechanism of resveratrol regulating hyperuricemic nephropathy is still not clear.

Resveratrol has a variety of biological effects, such as antioxidant stress, anti-inflammatory, antitumor, neuroprotection, and regulation of blood lipids. Furthermore, resveratrol has protective effects against gout, renal inflammation in diabetic rats, lipopolysaccharide-mediated acute renal injury, and renal ischemia–reperfusion injury in rats [9]. The mechanism may be related to the improvement of antioxidant enzyme activity, reduction of oxidative stress injury, anti-inflammatory effects, and inhibition of renal tissue cell apoptosis by resveratrol. In addition, resveratrol treatment has been reported to attenuate contrast-induced nephropathy and to inhibit the expression of interleukin (IL)-1β [10]. Moreover, in a model of polycystic kidney disease, resveratrol has been demonstrated to decrease the expression levels of monocyte chemoattractant protein-1 and tumor necrosis factor (TNF)-α in a dose-dependent manner [11]. Likewise, resveratrol has been shown to decrease the levels of the proinflammatory cytokines IL-1, IL-6, and TNF-α in the blood of rats with type 2 diabetes [12 13]. Thus, we hypothesized that resveratrol may protect against hyperuricemic nephropathy by regulating the inflammatory response.

In this study, resveratrol was used to interfere with a rat model of hyperuricemia with renal injury, which was induced by adenine and potassium oxinate. The anti-inflammatory and antioxidative effects of resveratrol in hyperuricemic rats were evaluated. The present study sheds light on the possible protective mechanism of resveratrol on hyperuricemic nephropathy.

MATERIALS AND METHODS

Animals

Specific pathogen-free male Sprague-Dawley rats (2 months old, 150–200 g, n = 40) were provided by the Guangdong Experimental Animal Center (certificate No.: 44007200044758, license No.: SCXK2013-0002). All animal experiments were approved by the Research Ethics Committee of Guangdong General Hospital (No. GDREC2017199A). Adaptive feeding was conducted for 1 week before the experiment, and the animals were allowed free access to food and water throughout the experiment.

Experimental protocol

After adaptive feeding for 1 week, 40 rats were randomly divided into the following 5 groups (8 mice per group): control group, hyperuricemia group, hyperuricemia with low-dose resveratrol (25 mg/kg, catalog number: CY170927, Yangling Ciyuan Biotechnology Co., Ltd., Xi'an, China) group, hyperuricemia with medium-dose resveratrol (50 mg/kg) group, and hyperuricemia with high-dose resveratrol (100 mg/kg) group [14].

To induce hyperuricemia [15], a drug mixture containing adenine (100 mg/kg/day, catalog number: rz1006, Shanghai Ruiyong Biological Technology Company, Shanghai, China) and potassium oxinate (1,000 mg/kg/day, TCI brand, Tokyo Chemical Industry Company, Tokyo, Japan; OSHA Haz Com: CFR 1910.1200) was diluted into a 200-mL suspension with distilled water. For the control group, the mice were fed with distilled water. For the hyperuricemia group, the mice were orally administered with the drug mixture (20 mL/kg/day). For the other three groups, the mice were fed with the drug mixture (20 mL/kg/day) in the morning and resveratrol (25, 50, or 100 mg/kg/day, respectively) in the afternoon. The experiments were performed for 21 days, and the body weight of each rat was recorded daily (Fig. 1A).

Fig. 1

The serum uric acid level in the hyperuricemia group after treatment with different dosages of resveratrol. (A) Adenine (100 mg/kg/day) and potassium oxinate (1,000 mg/kg/day) or vehicle were orally administered every morning. Low-dose (25 mg/kg/day), medium-dose (50 mg/kg/day), and high-dose (100 mg/kg/day) RES were administered every afternoon. (B) The serum levels of uric acid from the control or hyperuricemic rats treated without or with different concentrations of RES were measured. Samples were collected at 7, 14, and 21 days after treatment. Data are expressed as the mean ± SEM (n = 8).

RES, resveratrol; SEM, standard error of the mean; BUN, blood urea nitrogen.

^*P < 0.05, ^**P < 0.01 compared with the hyperuricemia group.

Biochemical analysis

For the collection of urine, all animals were allowed water but no food after the final gavage. Urine was collected for 24 h and was centrifugated at 3,500 rpm. The supernatant was used for biochemical analysis of the urinary protein contents, microalbuminuria, and β2-microglobulin.

For detection of various indicators in serum, blood was collected from the tail vein once on days 7, 14, and 21 in each group. After the urine was collected in each group, blood was collected from the abdominal aorta after intraperitoneal injection of 3% pentobarbital sodium (catalog number: SLBZ4028, Sigma-Aldrich, St. Louis, MO, USA) at a dose of 1 mL/kg, according to the body weight of the rats. The blood samples were placed at room temperature for 1 h and centrifuged at 2,500 rpm for 15 min. Serum was placed into a sterile Eppendorf tube and frozen at −80°C. The serum uric acid, urea nitrogen, and creatinine levels were determined using a Cobas 702 automated blood analyzer (Roche Diagnostics, Mannheim, Germany).

The mice were sacrificed after the experiment, and the capsule of the left kidney was removed on ice and weighed. The renal index was calculated as the kidney weight (g)/body weight (g) × 1,000.

Histopathological evaluation

The left kidney was fixed with 4% paraformaldehyde solution (catalog number: XS185005, Wuhan Servicebio Company, Wuhan, China), embedded in paraffin, sectioned, dewaxed, and hydrated. After conventional hematoxylin and eosin (H&E) staining, the morphological and structural changes of the renal tissues in each group were observed by optical microscopy at 200× magnification.

Enzyme-linked immunosorbent assay (ELISA)

The serum samples were collected and kept at −80°C. The malondialdehyde (MDA), superoxide dismutase (SOD), xanthine oxidase (XOD), total antioxidant capacity (TAOC), IL-1β, IL-6, and TNF-α levels were determined using rat ELISA kits (catalog numbers: mb-1926a, mb-1927a, mb-6649a, mb-6651a, mb-1588a, mb-1731a, and mb-1721a, respectively), according to the manufacturer's instructions. All these kits were purchased from the Jiangsu Microplate Biotechnology Company (Jiangsu, China).

Statistical analysis

All data were statistically analyzed using SPSS ver. 13.0 software. The measurement data are presented as the means ± standard error of the mean (SEM). The differences of means between multiple groups were compared using one-way analysis of variance. Dunnett's t-test was applied for the intergroup comparisons. The enumeration data are expressed as a percentage and were examined using the χ² test. P < 0.05 was considered to be statistically significant.

RESULTS

Effect of resveratrol on uric acid levels in rat serum

As shown in Fig. 1B, compared with the control group, the serum uric acid level in the hyperuricemia group was significantly increased (P < 0.01). Meanwhile, compared with the hyperuricemia group, the serum uric acid levels were decreased in the hyperuricemia groups treated with different dosages of resveratrol, especially in the high-dose group at 21 day (P < 0.01).

Effects of resveratrol on body weight and kidney indices in hyperuricemic rats

The body weight and kidney indices of the hyperuricemic rats are summarized in Fig. 2. There was no significant difference in the body weight between the control group and the model group (P > 0.05). However, there was a trend of weight loss in the groups treated with different dosages of resveratrol. Compared with the control group, the kidney indices in the hyperuricemia group were significantly increased (P < 0.01); while there were no obvious differences between the hyperuricemia group and the hyperuricemia groups treated with various dosages of resveratrol.

Fig. 2

The body weight and kidney indices of the hyperuricemic rats were measured after treatment with resveratrol. (A) The body weight and (B) kidney indices of the control or hyperuricemic rats treated without or with different concentrations of RES were measured at 0, 7, 14, and 21 days after treatment. Data are presented as the mean ± SEM (n = 8).

RES, resveratrol; SEM, standard error of the mean.

^**P < 0.01 compared with the hyperuricemia group.

Effects of resveratrol on the serum biochemical indicators in hyperuricemic rats

Compared with the control group, the serum levels of creatinine and urea nitrogen in the hyperuricemia group were significantly increased (P < 0.01). Meanwhile, compared with the hyperuricemia group, the levels of serum creatinine were decreased in the hyperuricemia groups treated with different dosages of resveratrol, especially in the high-dose group at 21 day (P < 0.01). However, there was no significant difference in the serum levels of urea nitrogen between the hyperuricemia group and the groups treated with different dosages of resveratrol (Fig. 3).

Fig. 3

The different doses of RES were administered every afternoon. (A) Serum urea nitrogen and (B) creatinine were measured to assess the renal function. Data are presented as the mean ± SEM (n = 8).

RES, resveratrol; SEM, standard error of the mean.

^*P < 0.05, ^**P < 0.01 compared with the hyperuricemia group.

Effects of resveratrol on urine biochemical indicators in hyperuricemic rats

As shown in Fig. 4, compared with the control group, the levels of urine protein contents, microalbumin, and β2-microglobulin in the hyperuricemia group were significantly increased (P < 0.01). Meanwhile, compared with the hyperuricemia group, the levels of microalbumin and β2-microglobulin were significantly decreased in each group treated with resveratrol, especially in the medium-dose group (P < 0.01). However, the level of urine protein contents was not significantly different between the hyperuricemia group and each resveratrol group.

Fig. 4

The levels of (A) urine protein contents, (B) microalbumin, and (C) β2-microglobulin in urine from the control or hyperuricemic rats treated without or with different concentrations of RES were measured. Data are presented as the mean ± SEM (n = 8).

RES, resveratrol; SEM, standard error of the mean.

^*P < 0.05, ^**P < 0.01 compared with the hyperuricemia group.

Effects of resveratrol on morphologic changes in hyperuricemic rat kidneys

Compared with a normal kidney size in the control group, the kidneys were swollen and had a white granular surface in the hyperuricemia group (Fig. 5). After H&E staining, the kidney slices in the hyperuricemia group were characterized by tubular dilatation, cast formation, edema, and even a decrease in the number of renal tubular epithelial cells, suggesting that the pathological injury of the kidney in each resveratrol group was improved to different degrees, especially in the medium- and high-dose groups.

Fig. 5

RES ameliorates renal morphological changes and reduces the infiltration of inflammatory cells in the kidney. Representative photographs of H&E-stained rat renal sections at a magnification of 200×. The groups were as follows: control group, hyperuricemia group (sham), hyperuricemia with low-dose RES, hyperuricemia with medium-dose RES, and hyperuricemia with high-dose RES. The blue arrows represent eosinophilic insoluble proteins; the black arrow represents salt crystals; and the green arrow represents edema of renal tubular epithelial cells.

RES, resveratrol; H&E, hematoxylin and eosin.

Effects of resveratrol on the inflammatory and oxidative responses

To further investigate the effects of resveratrol on the inflammatory and oxidative responses, the levels of MDA, SOD, TAOC, IL-1β, IL-6, and TNF-α in kidney tissue (Fig. 6) and the levels of SOD, XOD, TAOC, IL-1β, IL-6, and TNF-α in serum (Fig. 7) were evaluated by ELISA. Compared with the control group, the renal MDA level in the hyperuricemia group was significantly increased (P < 0.01); and it was decreased in each resveratrol group, especially in the medium-dose group. Compared with the control group, the serum level of XOD in the hyperuricemia group was significantly decreased; and it was increased by resveratrol treatment, especially in the high-dose group. In addition, compared with the control group, the levels of SOD and TAOC were decreased and the levels of IL-1β, IL-6, and TNF-α were increased in kidney tissue and serum; and these levels could be reversed by resveratrol treatment (all dosages).

Fig. 6

RES preserves rat renal function and reduces cytokine production induced by hyperuricemia. The concentrations of (A) MDA, (B) SOD, (C) TAOC, (D) IL-1β, (E) IL-6, and (F) TNF-α in kidney tissue were measured by ELISA. The groups were as follows: control group, hyperuricemia group, hyperuricemia with low-dose RES, hyperuricemia with medium-dose RES, and hyperuricemia with high-dose RES. Data are presented as the mean ± SEM (n = 8).

MDA, malondialdehyde; SOD, superoxide dismutase; TAOC, total antioxidant capacity; IL-1β, interleukin-1β; TNF-α, tumor necrosis factor-α; ELISA, enzyme-linked immunosorbent assay; RES, resveratrol.

^*P < 0.05, ^**P < 0.01 compared with the hyperuricemia group.

Fig. 7

The levels of (A) SOD, (B) TAOC, (C) XOD, (D) IL-1β, (E) IL-6, and (F) TNF-α in serum were measured by ELISA. The groups were as follows: control group, hyperuricemia group, hyperuricemia with low-dose RES, hyperuricemia with medium-dose RES, and hyperuricemia with high-dose RES. Data are presented as the mean ± SEM (n = 8).

SOD, superoxide dismutase; TAOC, total antioxidant capacity; XOD, xanthine oxidase; IL, interleukin; TNF, tumor necrosis factor; ELISA, enzyme-linked immunosorbent assay; RES, resveratrol.

^*P < 0.05, ^**P < 0.01 compared with the hyperuricemia group.

DISCUSSION

In the present study, a rat model of hyperuricemic nephropathy was successfully established by the oral administration of a mixture of adenine and potassium oxinate. Vesicular degeneration, glomerular atrophy, tubular dilatation, infiltration of inflammatory cells, and interstitial fibrosis were obviously observed in the hyperuricemia group. Resveratrol treatment could reduce the urea nitrogen, creatinine, and uric acid levels as well as the urinary protein contents. Furthermore, resveratrol exhibited obvious anti-inflammatory and antioxidative effects in hyperuricemic rats, suggesting that resveratrol may protect against hyperuricemic nephropathy by regulating the inflammatory and oxidative responses.

The innate immune system provides the first barrier to infection and disease through various processes including activation of inflammation. Inflammation is a biological process whereby immune cells, including macrophages, respond to and work together to eliminate damage from injury and disease. In this study, resveratrol treatment reversed the increased levels of IL-1β, IL-6, and TNF-α in kidney tissue and serum under hyperuricemic conditions, indicating that regulation of the inflammatory response may be a crucial part of resveratrol protecting against hyperuricemic nephropathy. Additionally, resveratrol has been demonstrated to alleviate acute kidney injury in lipopolysaccharide-treated mice [16] and to reduce the serum levels of TNF-α, IL-1β, and IL-6 in septic rats [17 18 19]. However, nuclear factor (NF)-related factor 2 signaling also has been shown to be regulated by resveratrol in sepsis-induced acute kidney injury [20]. In another study, resveratrol has been shown to ameliorate cyclosporine-induced renal injury [21]. Meanwhile, in cisplatin-treated mice, resveratrol decreased the interstitial leukocytic infiltration in kidney tissues and lowered the serum levels of urea, creatinine, IL-1β, and TNF-α. Furthermore, resveratrol protected against kidney injury in spontaneously hypertensive rats by inhibiting the expression of IL-6, intercellular adhesion molecule 1, and monocyte chemoattractant protein-1 [22]. It is interesting that pretreatment with resveratrol has been demonstrated to increase the mRNA expression of cytokine genes such as cyclooxygenase 2, TNF-α, IL-1β, IL-8, etc. [23]. Additionally, resveratrol treatment has been shown to increase TNF-α and NF-κB mRNA levels as well as to decrease caspase 3 cleavage in a rat renal ischemia–reperfusion injury model [24]. These findings were confirmed by the report by Li et al. [25], which revealed that resveratrol alleviates oxidative stress in the same animal model and lessens H₂O₂-induced NRK-52E cell apoptosis. However, resveratrol has shown no protective effect on ischemia-induced kidney injury in a rat model [26]. These discrepant results may be caused by the different conditions of kidney ischemia.

The protective mechanism of resveratrol also involves regulation of the oxidative response. Resveratrol has been shown to decrease intracellular reactive oxygen species levels via downregulation of the nicotinamide adenine dinucleotide phosphate oxidase subunits NOX1 and NOX4 in high glucose-treated human tubular epithelial cells (HK2) [27]. In addition, resveratrol has been demonstrated to ameliorate post-contrast acute kidney injury (PC-AKI) following diabetic nephropathy in vivo and in vitro [28]. Moreover, resveratrol reduced the expression levels of IL-1β and cell apoptosis in a PC-AKI model [10]. Furthermore, targeting renal oxidative stress with resveratrol could alleviate nicotine-induced renal injury [29]. These findings are in agreement with the results of this study. We found that the serum levels of key regulators of the oxidative response, such as SOD, XOD, and TAOC, were increased under hyperuricemic conditions and that these levels could be reversed by resveratrol treatment. Resveratrol also has been shown to activate manganese SOD in renal proximal tubule cells (NRK52E), thus protecting against nicotine-induced oxidative injury [30]. Moreover, supplementation of resveratrol improved glomerular filtration as well as decreased proteinuria, oxidative stress, and the levels of circulating SOD in a pig model of kidney autotransplantation [31]. Furthermore, the higher kidney tissue levels of MDA and the lower levels of reduced glutathione and activities of glutathione peroxidase and superoxide dismutase were reversed by resveratrol treatment [32]. Resveratrol also exhibited a protective effect against cisplatin-induced kidney oxidative injury in rabbits [33] and trifluralin toxicity in rats [34]. In addition, resveratrol has been shown to be protective against aluminum chloride-induced nephrotoxicity in rats as well as reduce renal oxidative stress and the inflammatory response [35].

In conclusion, we investigated the effect of resveratrol on hyperuricemia and kidney inflammation in adenine and potassium oxinate-induced hyperuricemic rats. The medium-dose and high-dose resveratrol groups showed good hypouricemic effects and inflammation-reducing effects in kidney tissue and serum. Thus, our results provide new evidence showing the effect of resveratrol on hyperuricemia and inflammation.

Notes

Funding: The present study was funded by Key Scientific and Technological Project of Guangdong Province (2016A020215222), Research Project of Traditional Chinese Medicine Bureau of Guangdong Province (20171006).

Conflict of Interest: The authors declare no potential conflicts of interests.

Author Contributions:

Conceptualization: Xiao B, Wang D.
Formal analysis: Xiao B, Zhang Y.
Funding acquisition: Wang D.
Investigation: Xiao B, Zheng Y, Li Z, Li Y.
Methodology: Xiao B, Wang D.
Supervision: Ma W, Wang D.
Writing - original draft: Xiao B, Wang D.
Writing - review & editing: Xiao B, Li D.

References

1. Adedeji AO, Pourmohamad T, Chen Y, Burkey J, Betts CJ, Bickerton SJ, Sonee M, McDuffie JE. Investigating the value of urine volume, creatinine, and cystatin C for urinary biomarkers normalization for drug development studies. Int J Toxicol. 2019; 38:12–22. PMID: 30673360.

2. Fidan C, Kantar A, Baskın E, Gülleroğlu K, Akdur A, Moray G, Haberal M. Effects of hyperuricemia on renal function in pediatric renal transplant recipients. Exp Clin Transplant. 2015; 13 Suppl 1:247–250.

3. Ghei M, Mihailescu M, Levinson D. Pathogenesis of hyperuricemia: recent advances. Curr Rheumatol Rep. 2002; 4:270–274. PMID: 12010614.

4. Lim AY, Teng GG. Allopurinol: a necessary evil. Singapore Med J. 2009; 50:925–926. PMID: 19787189.

5. Zhang W, Chen H, Sun C, Wu B, Bai B, Liu H, Shan X, Liang G, Zhang Y. A novel resveratrol analog PA19 attenuates obesity‑induced cardiac and renal injury by inhibiting inflammation and inflammatory cell infiltration. Mol Med Rep. 2019; 19:4770–4778. PMID: 31059027.

6. Pan QR, Ren YL, Zhu JJ, Hu YJ, Zheng JS, Fan H, Xu Y, Wang G, Liu WX. Resveratrol increases nephrin and podocin expression and alleviates renal damage in rats fed a high-fat diet. Nutrients. 2014; 6:2619–2631. PMID: 25025298.

7. Kitada M, Koya D. Renal protective effects of resveratrol. Oxid Med Cell Longev. 2013; 2013:568093. PMID: 24379901.

8. Shi YW, Wang CP, Liu L, Liu YL, Wang X, Hong Y, Li Z, Kong LD. Antihyperuricemic and nephroprotective effects of resveratrol and its analogues in hyperuricemic mice. Mol Nutr Food Res. 2012; 56:1433–1444. PMID: 22865646.

9. Kitada M, Kume S, Imaizumi N, Koya D. Resveratrol improves oxidative stress and protects against diabetic nephropathy through normalization of Mn-SOD dysfunction in AMPK/SIRT1-independent pathway. Diabetes. 2011; 60:634–643. PMID: 21270273.

10. Chen YH, Fu YC, Wu MJ. Does resveratrol play a role in decreasing the inflammation associated with contrast induced nephropathy in rat model? J Clin Med. 2019; 8:147.

11. Wu M, Gu J, Mei S, Xu D, Jing Y, Yao Q, Chen M, Yang M, Chen S, Yang B, Qi N, Hu H, Wüthrich RP, Mei C. Resveratrol delays polycystic kidney disease progression through attenuation of nuclear factor κB-induced inflammation. Nephrol Dial Transplant. 2016; 31:1826–1834. PMID: 27190325.

12. Huang DD, Shi G, Jiang Y, Yao C, Zhu C. A review on the potential of Resveratrol in prevention and therapy of diabetes and diabetic complications. Biomed Pharmacother. 2020; 125:109767. PMID: 32058210.

13. Den Hartogh DJ, Tsiani E. Health benefits of resveratrol in kidney disease: evidence from in vitro and in vivo studies. Nutrients. 2019; 11:11.

14. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 2006; 5:493–506. PMID: 16732220.

15. Zhu W, Pang M, Dong L, Huang X, Wang S, Zhou L. Anti-inflammatory and immunomodulatory effects of iridoid glycosides from Paederia scandens (LOUR.) MERRILL (Rubiaceae) on uric acid nephropathy rats. Life Sci. 2012; 91:369–376. PMID: 22910180.

16. Chen L, Yang S, Zumbrun EE, Guan H, Nagarkatti PS, Nagarkatti M. Resveratrol attenuates lipopolysaccharide-induced acute kidney injury by suppressing inflammation driven by macrophages. Mol Nutr Food Res. 2015; 59:853–864. PMID: 25643926.

17. Luo CJ, Luo F, Bu QD, Jiang W, Zhang W, Liu XM, Che L, Luan H, Zhang H, Ma RX, Sun JP, Xu Y. Protective effects of resveratrol on acute kidney injury in rats with sepsis. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2020; 164:49–56. PMID: 30994109.

18. Wang N, Mao L, Yang L, Zou J, Liu K, Liu M, Zhang H, Xiao X, Wang K. Resveratrol protects against early polymicrobial sepsis-induced acute kidney injury through inhibiting endoplasmic reticulum stress-activated NF-κB pathway. Oncotarget. 2017; 8:36449–36461. PMID: 28430592.

19. Gan Y, Tao S, Cao D, Xie H, Zeng Q. Protection of resveratrol on acute kidney injury in septic rats. Hum Exp Toxicol. 2017; 36:1015–1022. PMID: 27837177.

20. Wang Y, Feng F, Liu M, Xue J, Huang H. Resveratrol ameliorates sepsis-induced acute kidney injury in a pediatric rat model via Nrf2 signaling pathway. Exp Ther Med. 2018; 16:3233–3240. PMID: 30214546.

21. Bekpinar S, Karaca E, Yamakoğlu S, Alp-Yıldırım FI, Olgac V, Uydes-Doğan BS, Cibali E, Gultepe S, Uysal M. Resveratrol ameliorates the cyclosporine-induced vascular and renal impairments: possible impact of the modulation of renin-angiotensin system. Can J Physiol Pharmacol. 2019; 97:1115–1123. PMID: 31613143.

22. Xue HY, Yuan L, Cao YJ, Fan YP, Chen XL, Huang XZ. Resveratrol ameliorates renal injury in spontaneously hypertensive rats by inhibiting renal micro-inflammation. Biosci Rep. 2016; 36:e00339. PMID: 27129290.

23. Smith NC, Christian SL, Taylor RG, Santander J, Rise ML. Immune modulatory properties of 6-gingerol and resveratrol in Atlantic salmon macrophages. Mol Immunol. 2018; 95:10–19. PMID: 29367081.

24. Erkasap S, Erkasap N, Bradford B, Mamedova L, Uysal O, Ozkurt M, Ozyurt R, Kutlay O, Bayram B. The effect of leptin and resveratrol on JAK/STAT pathways and Sirt-1 gene expression in the renal tissue of ischemia/reperfusion induced rats. Bratisl Lek Listy (Tlacene Vyd). 2017; 118:443–448.

25. Li J, Li L, Wang S, Zhang C, Zheng L, Jia Y, Xu M, Zhu T, Zhang Y, Rong R. Resveratrol alleviates inflammatory responses and oxidative stress in rat kidney ischemia-reperfusion injury and H₂O₂-Induced NRK-52E Cells via the Nrf2/TLR4/NF-κB Pathway. Cell Physiol Biochem. 2018; 45:1677–1689. PMID: 29490296.

26. Bienholz A, Mae Pang R, Guberina H, Rauen U, Witzke O, Wilde B, Petrat F, Feldkamp T, Kribben A. Resveratrol does not protect from ischemia-induced acute kidney injury in an in vivo rat model. Kidney Blood Press Res. 2017; 42:1090–1103. PMID: 29207388.

27. He T, Guan X, Wang S, Xiao T, Yang K, Xu X, Wang J, Zhao J. Resveratrol prevents high glucose-induced epithelial-mesenchymal transition in renal tubular epithelial cells by inhibiting NADPH oxidase/ROS/ERK pathway. Mol Cell Endocrinol. 2015; 402:13–20. PMID: 25540919.

28. Wang Y, Wang B, Qi X, Zhang X, Ren K. Resveratrol protects against post-contrast acute kidney injury in rabbits with diabetic nephropathy. Front Pharmacol. 2019; 10:833. PMID: 31402864.

29. Ramalingam A, Santhanathas T, Shaukat Ali S, Zainalabidin S. Resveratrol supplementation protects against nicotine-induced kidney injury. Int J Environ Res Public Health. 2019; 16:16.

30. Hall S, Dixit M, Arany I. Resveratrol attenuates nicotine-mediated oxidative injury by inducing manganese superoxide dismutase in renal proximal tubule cells. In Vivo. 2017; 31:551–555. PMID: 28652419.

31. Soussi D, Danion J, Baulier E, Favreau F, Sauvageon Y, Bossard V, Matillon X, Turpin F, Belgsir EM, Thuillier R, Hauet T. Vectisol formulation enhances solubility of resveratrol and brings its benefits to kidney transplantation in a preclinical porcine model. Int J Mol Sci. 2019; 20:2268.

32. Ibrahim A, Al-Hizab FA, Abushouk AI, Abdel-Daim MM. Nephroprotective effects of benzyl isothiocyanate and resveratrol against cisplatin-induced oxidative stress and inflammation. Front Pharmacol. 2018; 9:1268. PMID: 30524274.

33. Cigremis Y, Akgoz M, Ozen H, Karaman M, Kart A, Gecer M, Atalan G. Resveratrol ameliorates cisplatin-induced oxidative injury in New Zealand rabbits. Can J Physiol Pharmacol. 2015; 93:727–735. PMID: 26243022.

34. Denek Z, Erbil G, Ozbal S, Micili SC, Ozogul C. The effects of resveratrol against trifluralin toxicity in the urinary tract of rats. Toxicol Ind Health. 2016; 32:106–117. PMID: 24021433.

35. Al Dera HS. Protective effect of resveratrol against aluminum chloride induced nephrotoxicity in rats. Saudi Med J. 2016; 37:369–378. PMID: 27052279.

TOOLS

Similar articles